1557. Population Pharmacokinetics of Suvratoxumab (MEDI4893), an Extended Half-life Staphylococcus aureus Alpha Toxin-Neutralizing Human Monoclonal Antibody, in Healthy Adults and Patients on Mechanical Ventilation in Intensive Care Units

BACKGROUND: Suvratoxumab (suvra), an extended half-life (~80 days), Staphylococcus aureus (SA) alpha toxin-neutralizing IgG monoclonal antibody, is under investigation for prevention of SA pneumonia in patients on mechanical ventilation (MV). We characterized the serum PK of suvra using population p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierre, Vadryn, Francois, Bruno, Hernandez-Illas, Martha, Sánchez Garcia, Miguel, Wu, Yuling, Eggimann, Philippe, Laterre, Pierre-Francois, Huberlant, Vincent, Viña, Lucia, Boulain, Thierry, Ruzin, Alexey, Bretonnière, Cédric, Pugin, Jerome, Trenado Álvarez, José, Bellamy, Terramika, Shoemaker, Kathryn, Ali, Omar, Lee, Nancy, Dequin, Pierre-Francois, Jafri, Hasan S, Roskos, Lorin, Colbert, Susan, Khan, Anis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809240/
http://dx.doi.org/10.1093/ofid/ofz360.1421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809240/
http://dx.doi.org/10.1093/ofid/ofz360.1421

Ejemplares similares